Impacto de Hormona Somatostatina y Analogos Radiomarcados en Diagnostico de Tumores Malignos.8
66. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273 - 82.
67. Lugtenburg PJ, Lo¨wenberg B,Valkema R et al. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin’s lymphomas. J Nucl Med 2001; 42: 222–9.
68. McMurry TJ, Brechbiel M, Kumar K & Gansow OA. Convenient Synthesis of Bifunctional Tetraaza Macrocycles. Bioconjugate Chem. 1992; 3:108 -17.
69. Traub T, Petkov V, Ofluoglu S et al. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 2001;42:1309–15.
70. Virgolini I, Szilvasi I, Kurtaran A et al. Indium-111In-DOTA-lanreotide: Biodistribution, safety, and radiation absorbed dose in tumor patients. J Nucl Med 1998; 39:1928–36.
71. De Jong M, Breeman WAP, Bakker WH et al. Comparison of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437–41.
72. De Jong M, Bakker WH, Krenning EP et al. Yttrium-90 and indium-111 labelling, receptor binding, and biodistribution of [DOTA0,D-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368–71.
73. Froidevaux S, Heppeler A, Eberle AN et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 2000;141:3304–12.
74. Papotti M, Croce S, Bello M, et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch 2001; 439:787–97.
75. Kwekkeboom DJ, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41: 1704-13
76. Ferone D, van Hagen MP, Kwekkeboom DJ, et al. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 2000; 85:1719 - 26.
77. Schulz S, Schmitt J, Weise W. Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. Gynecol Oncol 2003; 89:385- 90.
78. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30:781- 93.
79. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC and Maecke H R. Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy Clinical Cancer Research 2005;11:1136 - 45.
80. Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide.Semin Nucl Med 2002;32:92–6.
81. Maina T, Nock B, Nikolopoulou A et al. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptorpositive tumours: Synthesis and preclinical results. Eur J Nucl Med 2002;29:742–53.
82. Bangard M, Behe M, Guhlke S et al. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: First results in patients and comparison with 111In-DTPA-D-phe1-octreotide. Eur J Nucl Med 2000;27:628–37.
83. Decristoforo C, Mather SJ, Cholewinski W, et al. 99mTc-EDDA/ HYNIC-TOC: A new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: First clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318–25.
84. Guhlke S, Schaffland A, Zamora PO et al. 188Re- and 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: Approaches with pre- and postconjugate labeling. Nucl Med Biol 1998;25:621–31.
85. Eisenwiener KP, Prata MIM, Buschmann I et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002;13:530–41.
86. Okarvi S.M. Peptide-Based Radiopharmaceuticals: FutureTools for Diagnostic Imaging of Cancers and Other Diseases. Medicinal Research Reviews 2004; 24 ( 3): 357-97.
87. Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46:172S–8S.
88. Varagnolo L, Stokkel MPM, Mazzi U, Pauwels EKJ. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nucl Med Biol 2000; 27:103–12.
89. Kilbourn MR, Welch MJ. Fluorine-18 labeled receptor based radiopharmaceuticals. Appl Radiat Isot 1986; 37:677–83.
90. Walsh JC, Akhoon KM, Satyamurthy N et al Application of silicon-fluoride chemistry to fluorine-18 labeling agents for biomolecules: a preliminary note [abstract]. J Label Compds Radiopharm 1999; 42:S1–S3.
91. Guhlke S, Wester HJ, Bruns C, Stöcklin G. (2-[18F]Fluoropropionyl-( D)Phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol 1994; 21:819–25.
92. Hostetler ED, Edwards WB, Anderson CJ, Welch MJ. Synthesis of 4-[18F]fluorobenzoyl octreotide and biodistribution in tumour-bearing Lewis rats [abstract]. J Label Compds Radiopharm 1999; 42:S720–S722.
93. Li WP, Lewis JS, Kim J et al. DOTA-D-Tyr1-octreotate: A somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjug Chem 2002;13:721–8.
94. Kvols L K. & Woltering E A. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anti-Cancer Drugs 2006, 17:601–8.
95. Reubi JC, Eisenwiener KP, Rink H et al. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol. 2002; 456:45– 9.